Stoke Therapeutics, Inc. Gains 37.71%
Wed, Mar 27, 2024 at 07:18 PM
Stoke Therapeutics, Inc. (STOK:NASDAQ) jumped higher at $14.17, a gain of 37.7%. On Wed, Mar 27, 2024, STOK:NASDAQ hit a New 2-Week High of $14.17. The stock appeared on our News Catalysts scanner on Wed, Mar 27, 2024 at 12:00 PM in the 'BIOTECH' category. From Wed, Mar 13, 2024, the stock recorded 50.00% Up Days and 45.45% Green Days
About Stoke Therapeutics, Inc. (STOK:NASDAQ)
Stoke Therapeutics Inc is engaged in developing antisense oligonucleotide medicines. The medicine increases gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney.
Top 10 Gainers:
- iBio, Inc. (IBIO:NYSEMKT), 192.17%
- Republic First Bancorp, Inc. (FRBK:NASDAQ), 101.92%
- Cazoo Group Ltd Class A (CZOO:NYSE), 100.96%
- Destiny Tech100 Inc. (DXYZ:NYSE), 95.56%
- MariaDB plc (MRDB:NYSE), 94.25%
- two Class A (TWOA:NYSE), 71.47%
- Ontrak Inc. (OTRK:NASDAQ), 38.69%
- NuScale Power Corporation Class A (SMR:NYSE), 38.22%
- Nuvation Bio Inc. Class A (NUVB:NYSE), 37.85%
- Stoke Therapeutics, Inc. (STOK:NASDAQ), 37.71%